Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle

Jun 01 2007

Related Content

Pharma Catches a Break: Alzheimer's Drug Development Gets Rare Congressional Boost

Jun 01 2007

Back to Class: FDA Career Development Can Mean Faster Approvals

Jun 01 2007

Antibiotic Assistance

Jun 01 2007

FDA Resistant to Replidyne Approval

Jun 01 2007

Getting the Bugs Out of Antibiotic R&D: Commercial Implications of a Higher Regulatory Hurdle

Jun 01 2007

The Death of Arcoxia: Drug Regulation in a "Whistleblower" Climate

May 01 2007

Rethinking Phase IV: Congress Wants to Get Tough on Post-Marketing Requirements, but FDA May Soften the Blow

May 01 2007

Nervous Times for NDA Sponsors: The New Reality of FDA Drug Reviews

Apr 01 2007

The Politics of Drug Safety: An FDA Whistleblower's Push for Reform

Mar 01 2007

Flu Speed Ahead in Vaccines Market

Oct 01 2006

The FDA and Antibiotics: An Unsettled Agency of Many Minds

Jun 01 2002

Related Companies

Cardiovascular Systems, Inc.

Oscient Pharmaceuticals Corporation

Sanofi

Pfizer Inc.

Roche Holding AG

Sanofi

Bristol Myers Squibb Company

Abbott

Eli Lilly and Company

Wyeth

Cubist Pharmaceuticals, Inc.

Johnson & Johnson

Schering-Plough

Bayer AG

GSK plc

Pfizer Inc.

Elusys Therapeutics, Inc.

Sanofi

Cubist Pharmaceuticals, Inc.

Cardiovascular Systems, Inc.

Cubist Pharmaceuticals, Inc.

Cardiovascular Systems, Inc.

Forest Laboratories, Inc.

Cardiovascular Systems, Inc.

Additional Topics

Business Strategies BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window